- Published at
- by manilatimes.net
positive
positive
News for Interpace Biosciences, Inc. (IDXG)
- Published at
- by gurufocus.com
neutralneutralPancraGEN® Will Continue to be Offered While Interpace Re-evaluates its Previously Announced Re-structuring Plan
PARSIPPANY, NJ, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Interpace Diagnostics®, a subsidiary of Interpace Biosciences®, (”Interpace” or the ”Company”) (OT- Published at
- by manilatimes.net
neutralneutral- Published at
- by manilatimes.net
mixedmixedOTC Markets Group Announces the 2025 OTCQX Best 50
**media[515644]**VLU.LVLE.TOVHIBFVHI.VTGENRIOFFRIO.VQEPCPNWRFPBAMOTCMOGNRFOGN.VOBTCNWRCFNWRCDMAUTFMAU.VMARI.TOLUG.TOLUCCKSI.VKLD.VGUYGFGTWO.VGLASFGLAS-A.NEGBFHFTMNFFGOVFFGFHFBAYFFACOEMRRFCVALFCROJFCOV.VCOSOBUKSBRN.AXBRCHFBCHGAPM.VANPMFALDE.VADBRFACDVFAC.TOAAGFFAAG.V0R4M.LWLYYFWELL.TOPBNCOML.VOLNCFJAGGFJAG.TOIVPAFIVN.TOIDXGIDGGWCBWA- Published at
- by manilatimes.net
positivepositive- Published at
- by globenewswire.com
positivepositiveInterpace Biosciences Announces Record Third Quarter 2024 Financial and Business Results
●Q3 Revenue of $12.3 million; a $3.2M and 35% increase year-over-year ●Q3 Test volume up 26% year over year to record levels ●Q3 Cash collections of...- Published at
- by globenewswire.com
positivepositiveInterpace Biosciences Announces Capital Restructuring of Its Preferred Stock as a First Step Toward Seeking an Uplisting of Its Common Stock to Nasdaq
PARSIPPANY, NJ, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced that its...- Published at
- by globenewswire.com
positivepositiveInterpace Biosciences Announces Record Second Quarter 2024 Financial and Business Results
●Q2 Revenue of $12.0 million; a $1.0M and 9% increase year-over-year ●Q2 Test volume up 12% year-over-year to record levels ●Q2 Cash collections of...- Published at
- by globenewswire.com
neutralneutralInterpace Biosciences Announces First Quarter 2024 Financial and Business Results
●Q1 Revenue of $10.3 million; a 4% increase year-over-year ●Q1 Test volume up 10% year over year to record levels PARSIPPANY, NJ, May 09, 2024 ...- Published at
- by globenewswire.com
positivepositiveInterpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2023 Financial and Business Results
●Q4 and FY Revenue of $10.3 million and $40.2 million; a $8.4 million and 26% increase year-over-year ●Q4 and FY Income from Continuing Operations of $0.8...- Published at
- by globenewswire.com
positivepositiveInterpace Biosciences Announces Record Third Quarter 2023 Financial and Business Results
●Q3 Revenue of $9.1 million; an 11% increase year-over-year ●Q3 Test volume up 11% year-over-year ●Q3 Reimbursement improvement up 11% year-over-year,...- Published at
- by thestreet.com
mixedmixedWorldwide Next-Generation Sequencing Industry To 2025 - Key Drivers And Trends
DUBLIN, June 14, 2021 /PRNewswire/ -- The "Next-Generation Sequencing: Emerging Clinical Applications and Global Markets 2020-2025" report has been added toILU.DEILMN.MXILMNI1LM34.SAHTGMGH.MXGH0J8Z.LYGEN.LTMO.MXTMOTKBIFRYLPFROGN.MXROG.SWRO.SWRHHVFRHHBYRHHBFPSNLPHIAN.MXPHIA.DEPHIA.ASPHI1.DEPHG.BAPHGPACBONC.LNTRANSTGMYGNMYD.DEIDXGIDGGWFLGT.MXFLGTEPGNYEPGNFECX.DECGIXCDNAA1GI34.SAA.MXA688315.SS4974.T0TDF.L0R0H.L0QQ6.L0K3W.L0HAV.L084650.KQ038290.KQBIOCBDSXANPCYANPCFAGL.L300685.SZ000710.SZ- Published at
- by prnewswire.com
mixedmixedWorldwide Next-Generation Sequencing Industry to 2025 - Key Drivers and Trends
/PRNewswire/ -- TheILU.DEILMN.MXILMNI1LM34.SAHTGMGH.MXGH0J8Z.LYGEN.LTMO.MXTMOTKBIFRYLPFROGN.MXROG.SWRO.SWRHHVFRHHBYRHHBFPSNLPHIAN.MXPHIA.DEPHIA.ASPHI1.DEPHG.BAPHGPACBONC.LNTRANSTGMYGNMYD.DEIDXGIDGGWFLGT.MXFLGTEPGNYEPGNFECX.DECGIXCDNAA1GI34.SAA.MXA688315.SS4974.T0TDF.L0R0H.L0QQ6.L0K3W.L0HAV.L084650.KQ038290.KQBIOCBDSXANPCYANPCFAGL.L300685.SZ000710.SZ- Published at
- by prnewswire.com
mixedmixedGlobal COVID-19 Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) Medical Device Pipeline Market Assessment 2020-2021 Featuring Over 120 Companies
/PRNewswire/ -- The "COVID-19 Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) - Medical Devices Pipeline Assessment, 2020" report has been...- Published at
- by globenewswire.com
positivepositiveInterpace Biosciences Announces Contract for Thyroid Testing with Blue Cross Blue Shield of Illinois
In-network status for ThyGeNEXT® and ThyraMIR® with State’s Largest Payer PARSIPPANY, NJ, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences,...- Published at
- by marketscreener.com
positivepositiveInterpace Biosciences Announces Acceptance for Trading on the OTCQX
PARSIPPANY, NJ, Feb. 24, 2021 -- Interpace Biosciences, Inc. , an emerging leader in enabling personalized medicine, today announced that on February 24, 2021, the Company satisfied the... | February 24, 2021- Published at
- by thestreet.com
positivepositiveInterpace Biosciences Announces Acceptance For Trading On The OTCQX
PARSIPPANY, NJ, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCQX: IDXG) ("Interpace Biosciences" or the "Company"), an emerging leader in- Published at
- by rttnews.com
mixedmixedNKTR Teams Up With MRK, Pfizer Initiates Multiple Myeloma Trial, PCSA On Watch
Today's Daily Dose brings you news about Nektar's collaboration with Merck; Pfizer initiating a refractory multiple myeloma study; Processa Pharma's strategic financing; and vTv Therapeutics' initiation of a phase 1 multiple ascending dose study of HPP737.- Published at
- by markets.businessinsider.com
positivepositiveInterpace Biosciences Announces Path Forward in Letter to Shareholders
PARSIPPANY, NJ, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) (“Interpace”), a leader in enabling personalized me...- Published at
- by rttnews.com
positivepositiveStock Alert: Interpace Biosciences Gain 15%
Shares of Interpace Biosciences Inc. (IDXG) are gaining nearly 15% on Thursday morning after the company announced a contract for thyroid testing with Blue Cross Blue Shield of Florida.